All Brands Owned by Abbott Laboratories

What does Abbott Laboratories own?
Abbott Laboratories owns brands across nutrition (Similac, Ensure, PediaSure, Pedialyte), medical devices (FreeStyle Libre, Volt, TactiFlex, Amulet), and diagnostics (Cologuard, BinaxNOW, Alinity). The company acquired Exact Sciences in March 2026 for $21 billion, adding Cologuard and other molecular diagnostic products.

Is Abbott Laboratories publicly traded?
Yes, Abbott Laboratories trades on the New York Stock Exchange under the ticker symbol ABT. The company has been publicly listed since 1929 and is a component of the S&P 500 Index.

Who founded Abbott Laboratories?
Abbott was founded in 1888 by Dr. Wallace Calvin Abbott, a physician in Ravenswood, Illinois (now part of Chicago). He began by manufacturing reliable dosimetric granules for pharmaceutical use.

Where is Abbott Laboratories headquartered?
Abbott is headquartered in Abbott Park, North Chicago, Illinois, USA. The company operates in more than 160 countries globally.

How many brands does Abbott Laboratories own?
Abbott owns numerous brands across its four segments. Key consumer brands include Similac, Ensure, PediaSure, and Pedialyte in nutrition. Key medical device brands include FreeStyle Libre, Volt, and Amulet. Key diagnostics brands include Cologuard, BinaxNOW, and Alinity.

Who owns Abbott Laboratories?
Abbott Laboratories is a publicly traded company with shares held by institutional investors, mutual funds, and individual shareholders. The company is led by Chairman and CEO Robert B. Ford.

What is Abbott Laboratories' revenue?
Abbott reported Q2 2026 sales of $12.59 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. The company reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised adjusted diluted EPS guidance to $5.45 to $5.60.

Did Abbott acquire Exact Sciences?
Yes, Abbott completed the $21 billion acquisition of Exact Sciences in March 2026. The acquisition added Cologuard, a noninvasive colorectal cancer screening test, to Abbott's diagnostics portfolio. Diagnostics sales grew 42% year over year in Q2 2026, the first full quarter including Exact Sciences results.